Company Description
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.
It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke and traumatic brain injury.
The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.
In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening.
Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells.
International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.
| Country | Canada |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. Andrey Semechkin Ph.D. |
Contact Details
Address: 5950 Priestly Drive Carlsbad, California 92008 United States | |
| Phone | 760-940-6383 |
| Website | internationalstemcell.com |
Stock Details
| Ticker Symbol | ISCO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001355790 |
| CUSIP Number | 460378102 |
| ISIN Number | US4603782016 |
| Employer ID | 20-4494098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrey Semechkin Ph.D. | Co-Chairman of the Board and Chief Executive Officer |
| Dr. Russell Kern Ph.D. | Executive Vice President, Chief Scientific Officer, Principal Financial Officer and Director |
| Rebecca McGee M.B.A. | President of Lifeline Cell Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Sep 27, 2023 | DEF 14C | Filing |
| Sep 18, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| Jun 21, 2023 | 8-K | Current Report |
| May 12, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | ARS | Filing |
| Apr 28, 2023 | DEF 14A | Other definitive proxy statements |